Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Tuesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is expected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Zentalis Pharmaceuticals to post earnings of ($0.74) per share for the quarter.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $2.32 on Friday. The firm has a market cap of $165.32 million, a price-to-earnings ratio of -0.93 and a beta of 1.81. Zentalis Pharmaceuticals has a fifty-two week low of $1.61 and a fifty-two week high of $18.07. The firm has a fifty day moving average price of $2.55 and a two-hundred day moving average price of $3.08.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Wedbush reissued a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Wells Fargo & Company cut their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. UBS Group cut their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Guggenheim dropped their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, HC Wainwright dropped their price objective on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.24.

Insider Activity at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns acquired 20,000 shares of the firm’s stock in a transaction on Thursday, February 6th. The shares were purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the purchase, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jan Skvarka acquired 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the purchase, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.